Kevin Patrick Moran

Kevin Patrick Moran (finance chief) discloses dealings in Vanda Pharmaceuticals Inc. to SEC (Form 4). The record holds 16 filings, for trades running from 28 July 2021 to 2 March 2026.

Both buying and selling appear: 1 purchase worth €8,360, against 8 sales worth €534k. Sales outweigh purchases by €526k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 6 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 1 sale.

Most recently, on 4 March 2026, the filings show an open-market sale worth €298k in Vanda Pharmaceuticals Inc. The most recent open-market purchase was published on 24 February 2025, 601 days ago. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.